OptimizeRx (NASDAQ:OPRX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Saturday, Wall Street Zen reports.
OPRX has been the topic of a number of other reports. Stifel Nicolaus lowered their price target on OptimizeRx from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Thursday, November 12th. B. Riley Financial reaffirmed a "buy" rating and set a $10.50 price target (down from $11.00) on shares of OptimizeRx in a report on Thursday, November 12th. UBS Group set a $11.00 price target on shares of OptimizeRx in a research note on Friday, August 14th. Citizens Jmp boosted their price objective on shares of OptimizeRx from $9.00 to $11.00 and gave the company a "market outperform" rating in a report on Friday, August 14th. Finally, Citigroup restated a "market outperform" rating on shares of OptimizeRx in a research report on Tuesday, October 27th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.21.
Read Our Latest Research Report on OptimizeRx
OptimizeRx Stock Performance
Shares of OptimizeRx stock opened at $6.70 on Friday. The stock has a market cap of $126.70 million, a price-to-earnings ratio of 26.80 and a beta of 1.20. The firm's 50-day moving average is $8.38 and its 200 day moving average is $7.11. OptimizeRx has a 1 year low of $4.54 and a 1 year high of $15.59. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.06 and a quick ratio of 5.58.
OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 11th. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.16 by $0.04. The business had revenue of $21.61 million during the quarter, compared to analyst estimates of $21.19 million. OptimizeRx had a net margin of 5.33% and a return on equity of 9.58%. Sell-side analysts anticipate that OptimizeRx will post 0.48 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the stock. Algert Global LLC bought a new position in shares of OptimizeRx in the third quarter worth about $260,000. Mink Brook Asset Management LLC grew its position in shares of OptimizeRx by 254.4% during the third quarter. Mink Brook Asset Management LLC now owns 500,483 shares of the company's stock worth $4,179,000 after purchasing an additional 359,248 shares in the last quarter. Jump Financial LLC bought a new stake in OptimizeRx during the 3rd quarter valued at approximately $124,000. Marshall Wace LLP raised its stake in OptimizeRx by 183.2% during the 3rd quarter. Marshall Wace LLP now owns 459,362 shares of the company's stock valued at $3,836,000 after purchasing an additional 297,176 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in OptimizeRx in the 3rd quarter worth approximately $1,670,000. 76.47% of the stock is currently owned by institutional investors.
About OptimizeRx
(
Get Free Report)
OptimizeRx is a healthcare technology company that connects life sciences companies with healthcare professionals and patients through digital communications. Its platform uses channels such as electronic health records and other clinical workflows to deliver relevant information at the point of care. The company's services support programs for medication access and affordability, patient education and engagement, and communication between healthcare providers and life sciences organizations. OptimizeRx also provides tools intended to help life sciences companies reach clinicians and patients through digital channels.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.